Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Penel

Showing results (1-10 of 350) with videos related to

Pageof 35
Sort By:
Bulletin Du Cancer|April 18, 2018
[Requirement of DPD deficiency screening before prescription of fluoropyrimidines]Nicolas Penel
Bulletin Du Cancer|December 4, 2016
[Carcinoma of unknown primary site: From necropsy to epigenetic analysis]Nicolas Penel
Bulletin Du Cancer|December 25, 2016
[β-catenin and desmoid tumors: The ideal biomarker?]Nicolas Penel
Bulletin Du Cancer|December 18, 2022
Why collect data on "Races/Ethnicity" in cancer clinical trials? A letter from a french investigatorNicolas Penel
Bulletin Du Cancer|October 8, 2016
[Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials]Nicolas Penel
Bulletin Du Cancer|September 7, 2016
[ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients]Nicolas Penel
Bulletin Du Cancer|July 10, 2017
[2017 ASCO: Complete androgen blockade strikes back]Nicolas Penel
Bulletin Du Cancer|June 18, 2016
[Phase 1 of clinical trial: The issue of dose-escalating]Nicolas Penel
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Diagnostic management of inaugurable metastases]Nicolas Penel
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Prognosis and possibilities of treatment of inaugural metastases]Nicolas Penel
Pageof 35

Showing results (1-10 of 350) with videos related to

Sort By:
Pageof 35
Bulletin Du Cancer|April 18, 2018
[Requirement of DPD deficiency screening before prescription of fluoropyrimidines]Nicolas Penel
Bulletin Du Cancer|December 4, 2016
[Carcinoma of unknown primary site: From necropsy to epigenetic analysis]Nicolas Penel
Bulletin Du Cancer|December 25, 2016
[β-catenin and desmoid tumors: The ideal biomarker?]Nicolas Penel
Bulletin Du Cancer|December 18, 2022
Why collect data on "Races/Ethnicity" in cancer clinical trials? A letter from a french investigatorNicolas Penel
Bulletin Du Cancer|October 8, 2016
[Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials]Nicolas Penel
Bulletin Du Cancer|September 7, 2016
[ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients]Nicolas Penel
Bulletin Du Cancer|July 10, 2017
[2017 ASCO: Complete androgen blockade strikes back]Nicolas Penel
Bulletin Du Cancer|June 18, 2016
[Phase 1 of clinical trial: The issue of dose-escalating]Nicolas Penel
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Diagnostic management of inaugurable metastases]Nicolas Penel
Presse Medicale (Paris, France : 1983)|July 24, 2003
[Prognosis and possibilities of treatment of inaugural metastases]Nicolas Penel
Pageof 35